Utah Medical Products, Inc. Reports Results of Tender Offer

By ValueTheMarkets

1 min read

Utah Medical Products, Inc. (NASDAQ:UTMD) offered to purchase up to 650,000 shares of its common stock at $75.00 per share. The issuer Tender Offer expired...

SALT LAKE CITY, UT / ACCESS Newswire / October 29, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) offered to purchase up to 650,000 shares of its common stock at $75.00 per share. The issuer Tender Offer expired Tuesday October 27.

In short, 322,215 shares were purchased for $24,166,125. Remaining UTMD shares outstanding at this date are 2,854,566 including 1,775 employee option exercises in October.

In addition, $107,660 administration fees will be paid to Georgeson/Computershare Inc., and $6,732 in filing fees to the SEC. The effective cost of the tender offer was 75.36/ share. Another 1% excise tax will be levied by the federal government on share repurchases.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.

Contact:

Brian Koopman
(801) 566-1200

SOURCE: Utah Medical Products, Inc.


View the original press release on ACCESS Newswire

A sharper way to see the markets in just 5 minutes.

Same news, different lens. We cut through the noise and hand you the overlooked ideas and the deeper read the crowd misses. Join 38,000+ investors seeing the markets differently.

I agree to the privacy policy.

Explore more on these topics:

Important Notice And Disclaimer

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.